{
  "ticker": "JNJ",
  "target_date": "2025-08-08",
  "actual_date": "2025-08-08",
  "collected_at": "2025-12-08T12:07:09.970169",
  "price": {
    "open": 168.7,
    "high": 171.6,
    "low": 168.08,
    "close": 170.98141479492188,
    "volume": 7686800,
    "change_1d_pct": 1.05,
    "change_7d_pct": 3.63,
    "change_30d_pct": 14.03
  },
  "technicals": {
    "rsi_14": 69.26,
    "sma_20": 164.42,
    "sma_50": 157.15,
    "macd": 3.711,
    "macd_signal": 3.457,
    "macd_histogram": 0.253,
    "bb_upper": 173.53,
    "bb_lower": 155.31,
    "price_vs_sma20_pct": 3.99,
    "price_vs_sma50_pct": 8.8,
    "volume_ratio": 0.81
  },
  "fundamentals": {
    "market_cap": 489009807360,
    "pe_ratio": 19.591507,
    "forward_pe": 19.147924,
    "price_to_book": 6.16044,
    "price_to_sales": 5.3067293,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.33,
    "pct_from_52w_low": 44.28
  },
  "macro": {
    "spy": {
      "price": 635.42,
      "change_1d_pct": 0.78,
      "change_7d_pct": 0.81
    },
    "vix": {
      "level": 15.15,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.28
    },
    "dollar_index": {
      "level": 98.18
    },
    "gold": {
      "price": 3439.1
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season",
      "source": "Yahoo",
      "datetime": 1754664420,
      "summary": "AMGN posts strong Q2 results as Repatha, Evenity, Blincyto and rare disease drugs power broad-based volume gains.",
      "url": "https://finnhub.io/api/news?id=3b5f04f5b0fc4631a803f58dc346eb98f823be34ed648cd4464c5fe9449b2442"
    },
    {
      "headline": "Sigmoidoscopes Market Insights, Competitive Landscape, and Forecast 2022-2024 & 2025-2032 | North America, Healthcare Advancements and Geriatric Populations Drive Growth",
      "source": "Yahoo",
      "datetime": 1754651580,
      "summary": "The sigmoidoscopes market, segmented by product type, usability, end-user, and geography, is forecasted to grow at a 5.57% CAGR from 2025 to 2032. This growth is driven by rising chronic conditions, a growing geriatric population, and increased awareness about early diagnosis of gastrointestinal dis",
      "url": "https://finnhub.io/api/news?id=af69c2ae06a392ff1db66938ee6cfe422a0131f3b50aefa6ced60a3e3e02dd00"
    },
    {
      "headline": "Genmab raises full-year outlook, shares rise",
      "source": "Yahoo",
      "datetime": 1754585315,
      "summary": "Investing.com -- Genmab raised its full-year revenue and profit guidance on Thursday, driven by stronger-than-expected royalties from key partner drugs.",
      "url": "https://finnhub.io/api/news?id=479680a0c71618a0997680d2f2495e0fd6d78bdc9adfd392c4720d3c238d2939"
    },
    {
      "headline": "Is Encompass Health (EHC) Outperforming Other Medical Stocks This Year?",
      "source": "Yahoo",
      "datetime": 1754574002,
      "summary": "Here is how Encompass Health (EHC) and Johnson & Johnson (JNJ) have performed compared to their sector so far this year.",
      "url": "https://finnhub.io/api/news?id=d57ff8fcf81e6dfb3cb447f1a69a04455bf279b4a638c372a82a56f5395db41c"
    },
    {
      "headline": "United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda",
      "source": "Yahoo",
      "datetime": 1754570460,
      "summary": "The United States Pharmaceutical Market is projected to reach $979.25 billion by 2033, from $638.86 billion in 2024, at a CAGR of 4.86% (2025-2033). Growth is driven by rising chronic diseases, demand for innovative medicines, and advanced biotech solutions. High R&D investments in oncology, neurolo",
      "url": "https://finnhub.io/api/news?id=c5faab32289036b61d1de41f603a0cb2c73c4612692dcf7386f42a8f151806d8"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "10-Q",
      "date": "2025-07-24",
      "description": "jnj-20250629.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000178/jnj-20250629.htm"
    },
    {
      "form": "13F-HR",
      "date": "2025-07-22",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445425000367/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "4",
      "date": "2025-07-18",
      "description": "xslF345X05/wk-form4_1752869553.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000172/xslF345X05/wk-form4_1752869553.xml"
    },
    {
      "form": "8-K",
      "date": "2025-07-16",
      "description": "jnj-20250716.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000170/jnj-20250716.htm"
    },
    {
      "form": "4",
      "date": "2025-06-12",
      "description": "xslF345X05/wk-form4_1749760336.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000156/xslF345X05/wk-form4_1749760336.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}